BioTuesdays

Author - Stephen Kilmer

NRx-Pharma-Logo
Markets

Dawson James starts NRx Pharma at buy; PT $3.00

Dawson James Securities initiated coverage of NRx Pharmaceuticals (NASDAQ:NRXP) with a “buy” rating and $3.00 price target. The stock closed at 68 cents on March 16. NRx Pharmaceuticals is a clinical-stage...

March 17, 2023
Theseus-Logo
Markets

Stifel starts Theseus Pharma at buy; PT $24

Stifel initiated coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and $24 price target. The stock closed at $7.35 on March 15. Theseus is a clinical-stage, small molecule oncology company that...

March 16, 2023
CymaBay-Logo
Markets

BTIG starts CymaBay at buy; PT $15

BTIG launched coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $15 price target. The stock closed at $9.11 on March 8. Analyst Julian Harrison writes that the company’s seladelpar is well...

March 9, 2023
Mesoblast-Logo
Markets

WB starts Mesoblast at OP; fair value estimate $8

William Blair initiated coverage of Mesoblast (NASDAQ:MESO) with an “outperform” rating and fair value estimate of $8. The stock closed at $3.03 on March 8. Mesoblast is developing mesenchymal lineage cell-derived...

March 9, 2023
MoonLake Logo
Markets

BTIG starts Moonlake at buy; PT $36

BTIG initiated coverage of Moonlake Immunotherapeutics (NASDAQ:MLTX) with a “buy” rating and $36 price target. The stock closed at $23.70 on March 8. “We see Moonlake’s sonelokimab (SLK) well-positioned to emerge as the...

March 9, 2023
Mineralys-logo
Markets

Stifel starts Mineralys at buy; PT $45

Stifel launched coverage of Mineralys Therapeutics (NASDAQ:MLYS) with a “buy” rating and 12-month price target of $45. The stock closed at $18.96 on March 7. Mineralys’ lorundrostat is targeting hyperaldosteronism, a...

March 7, 2023
Structure-Therapeutics-Logo
Markets

SVB starts Structure Therapeutics at OP; PT $33

SVB Securities initiated coverage of Structure Therapeutics (NASDAQ:GPCR) with an “outperform” rating and $33 price target. The stock closed at $24 on Feb. 27. “Our investment thesis is that the company’s platform and...

February 28, 2023
Disc-Medicine-Logo
Markets

SVB starts Disc Medicine at OP; PT $36

SVB Securities launched coverage of Disc Medicine (NASDAQ:IRON) with an “outperform” rating and $36 price target. The stock closed at $24.39 on Feb. 27. Disc Medicine is a clinical-stage biopharmaceutical company...

February 28, 2023
Orchestra-Biomed-Logo
Markets

Piper starts Orchestra Biomed at OW; PT $15

Piper Sandler launched coverage of Orchestra Biomed (NASDAQ:OBIO) with an “overweight” rating and $15 price target. The stock closed at $10.30 on Feb. 23. The company develops solutions in cardiac neuromodulation and...

February 24, 2023